Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 536Neoplasms 432Carcinoma, Non-Small-Cell Lung 403Prostatic Neoplasms 334Colorectal Neoplasms 302Lung Neoplasms 262Multiple Myeloma 229Neoplasm Metastasis 186Leukemia, Myeloid, Acute 183Pancreatic Neoplasms 182Ovarian Neoplasms 166Melanoma 143Squamous Cell Carcinoma of Head and Neck 137Recurrence 114Carcinoma, Hepatocellular 113Carcinoma, Renal Cell 112Precursor Cell Lymphoblastic Leukemia-Lymphoma 111Stomach Neoplasms 109Lymphoma 109Head and Neck Neoplasms 108Endometrial Neoplasms 105Brain Neoplasms 104Lymphoma, Non-Hodgkin 102Glioblastoma 99Urinary Bladder Neoplasms 93Triple Negative Breast Neoplasms 92Uterine Cervical Neoplasms 89Hematologic Neoplasms 88Lymphoma, Large B-Cell, Diffuse 84Leukemia, Lymphocytic, Chronic, B-Cell 83

Interventions

temsirolimus 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × 30 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡